1. Lifeward partnered with Verita Neuro for ReWalk distribution in new markets. 2. Collaboration aims to enhance patient access to rehabilitation technology. 3. Potential market size for ReWalk is estimated at $1.75 billion. 4. New in-patient training model expected to support clinical adoption. 5. Verita Neuro has a database of 25,000 spinal cord injury patients.
FAQ
Why Bullish?
The distribution agreement expands Lifeward's market reach and potential revenue streams. Historical growth in the medical technology sector supports positive expectations.
How important is it?
The article highlights significant growth opportunities for Lifeward through new partnerships, which can influence its future performance positively.
Why Long Term?
The strategic partnership will build Lifeward’s presence over time, tapping into new patient bases. Similar agreements have previously led to sustained growth in healthcare companies.
Related Companies
Lifeward Expands Global Reach of ReWalk® Personal Exoskeleton
On December 17, 2025, Lifeward Ltd. (Nasdaq: LFWD) announced a strategic expansion of its international distribution for the ReWalk Personal Exoskeleton. Through a new partnership with Verita Neuro, the Singapore-based healthcare company, Lifeward aims to enhance patient access to this innovative technology across Mexico, Thailand, and the United Arab Emirates (UAE).
Details of the Distribution Agreement
This distribution agreement signifies a critical step in Lifeward’s long-term strategy to extend its commercial presence into high-potential markets. Verita Neuro is set to be the exclusive distributor of the ReWalk system in the aforementioned countries, leveraging its extensive network of rehabilitation centers and a database of over 25,000 spinal cord injury (SCI) patients.
- Countries involved: Mexico, Thailand, and UAE
- Potential market: Over 7 million spinal cord injury survivors worldwide
- Estimated total addressable market: $1.75 billion
New Training and Rehabilitation Model
As part of this collaboration, Verita Neuro will implement an advanced delivery model that includes patient-specific setup and training within an in-patient rehabilitation program. This approach aims to enhance the clinical adoption of ReWalk in various rehabilitation settings and serves as an alternative to traditional outpatient rehabilitation protocols.
Company Perspectives
Mark Grant, CEO of Lifeward, emphasized that this distribution agreement aligns with the company's mission to broaden global access to the ReWalk Exoskeleton. “The Company’s hybrid commercial model, combining direct sales in the United States with third-party distribution in international markets, is designed to improve sales volumes while maintaining manageable operating expenses,” he stated.
Julian Andriesz, CEO of Verita Neuro, remarked, “We are excited to empower our patients with cutting-edge robotic physical rehabilitation systems. Through Lifeward’s ReWalk Exoskeleton in our inpatient program, we’re achieving another world first, seamless multimodal enablement.”
About Lifeward and Verita Neuro
Lifeward is dedicated to designing and commercializing transformative solutions in the fields of physical rehabilitation and recovery. With a commitment to innovation, Lifeward offers a wide range of products, including the ReWalk Exoskeleton and AlterG Anti-Gravity System.
Verita Healthcare, formed by Verita Neuro, positions itself as a leading integrated healthcare group. With a strong emphasis on precision diagnostics and advanced Med-Tech solutions, Verita Neuro focuses on revolutionary treatments for those affected by neurological conditions.
Conclusion
The partnership between Lifeward and Verita Neuro is set to enhance the rehabilitation landscape for spinal cord injury patients by providing state-of-the-art assistive technology. This innovative approach not only expands the market reach for Lifeward (LFWD) but also aims to deliver unparalleled benefits to patients navigating their recovery journey.